Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Multiple Oral Doses of BAY1834845 in Healthy Male Subjects and in Female and Male Patients With Psoriasis Over an Extended Treatment Duration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2021
Price :
$35
*
At a glance
- Drugs Zabedosertib (Primary) ; Midazolam
- Indications Plaque psoriasis; Psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 25 Feb 2021 Status changed from active, no longer recruiting to completed.
- 24 Jan 2021 Planned End Date changed from 12 Jan 2021 to 29 Jan 2021.
- 22 Dec 2020 Planned End Date changed from 11 Dec 2020 to 12 Jan 2021.